Skip to main content
NewslettersWatchlist

Bioxcel Therapeutics Inc(BTAI-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.06
Day High2.19
Open:2.10
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
MarketBeat
Unlocking AI investment opportunities in healthcare
AllPennyStocks.com
Strong Open For Biotech Shares Following Phase 3 Comments
Motley Fool
Why Shares of BioXcel Therapeutics Fell This Week
PR Newswire
Important September 5, 2023 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit
PR Newswire
BTAI DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI
PR Newswire
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options
PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline
PR Newswire
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
PR Newswire
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc.(BTAI) Shareholders
PR Newswire
BTAI CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. (BTAI) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm
PR Newswire
BIOXCEL INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options
PR Newswire
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
PR Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI
PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline
PR Newswire
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit
PR Newswire
BIOXCEL SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options
PR Newswire
BIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
PR Newswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
PR Newswire
Securities Class Action Reminder for (BTAI) Investors: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
PR Newswire
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Motley Fool
Why BioXcel Therapeutics Stock Flopped Again Today
PR Newswire
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit
PR Newswire
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
Motley Fool
Why BioXcel Therapeutics Stock Is Getting Crushed Today
PR Newswire
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind BioXcel Investors of a Lead Plaintiff Deadline of September 5, 2023
TheNewswire.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
TheNewswire.com
ROSEN, A RESPECTED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
PR Newswire
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options
PR Newswire
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI

Profile

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.